Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CTMX
vs
S&P 500
CTMX
S&P 500
Over the past 12 months, CTMX has underperformed S&P 500, delivering a return of -23% compared to S&P 500's +16% growth.
Stocks Performance
CTMX vs S&P 500
Performance Gap
CTMX vs S&P 500
Performance By Year
CTMX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CytomX Therapeutics Inc
Glance View
CytomX Therapeutics is a biotechnology company that develops cancer drugs built around its Probody technology. Its core idea is to keep an antibody-like drug “masked” while it travels through the body, then let it switch on mainly in tumor tissue. The company is trying to make cancer treatments more selective, so they attack tumors while limiting damage to healthy cells. The company does not sell a broad lineup of approved medicines. Instead, it works on drug candidates of its own and also partners with larger pharmaceutical companies to apply its technology to their antibody programs. CytomX makes money mainly through collaboration payments, research funding, milestone payments, and royalties if partnered drugs reach the market. Its main customers are not end patients in the usual sense; they are drug-development partners, and eventually hospitals, doctors, and patients if any program becomes an approved therapy. What makes CytomX different is that it sits at the intersection of drug discovery and platform licensing: it is trying to turn a technology for masking biologic drugs into a safer way to build targeted cancer treatments.